Palonosetron | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Palonosetron
US Patents

Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Contact Supplier

Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

Contact Supplier

xyz-pharma-m-2025-03-24

Contact Supplier

Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

xyz-pharma-m-2025-03-17

Contact Supplier

Palonosetron

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

41 API Suppliers, 22 USDMF, 3 JDMF, 8 EU WC, 4 KDMF, 13 NDC API, 23 Listed Suppliers, $ API Reference Price

41 API Suppliers
22 USDMF
3 JDMF
8 EU WC
4 KDMF
13 NDC API
23 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

12 Drugs in Development

12 Drugs in Development

INTERMEDIATES

11 Intermediate Suppliers

11 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

91 FDF Dossiers, 34 FDA Orange Book, 20 Europe, 2 Canada, 6 Australia, 8 South Africa, 21 Listed Dossiers

91 FDF Dossiers
34 FDA Orange Book
20 Europe
2 Canada
6 Australia
8 South Africa
21 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 300MG;EQ 0.5MG BASE, SOLUTION;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML), POWDER;INTRAVENOUS - EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL, SOLUTION;INTRAVENOUS - EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML), INJECTABLE;INTRAVENOUS - EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 300MG;EQ 0.5MG BASE
SOLUTION;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)
POWDER;INTRAVENOUS - EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL
SOLUTION;INTRAVENOUS - EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)
INJECTABLE;INTRAVENOUS - EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
INJECTABLE;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE;ORAL - EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Minakem, 2 Rochem International Inc, 16 SPI Pharma, 7 DKSH, 3 Faran Shimi Pharmaceutical, 3 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 6 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 Pramukh Pharmachem, 1 Zeal MediPharma, 4 ACG Worldwide, 6 Actylis, 1 Alcedo Pharmachem, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 BASF, 3 DFE Pharma, 5 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 6 Kerry, 3 Lonza Capsugel, 9 Microlex e.U, 1 NEWEDGE Overseas, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 22 Roquette, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 9 Sigachi Industries, 1 Ulanqab Kema New Material, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

47 Fillers, Diluents & Binders, 19 Disintegrants & Superdisintegrants, 18 Direct Compression, 16 Thickeners and Stabilizers, 16 Lubricants & Glidants, 15 Taste Masking, 14 Chewable & Orodispersible Aids, 12 Parenteral, 12 Co-Processed Excipients, 11 Coating Systems & Additives, 11 Film Formers & Plasticizers, 10 Granulation, 8 Empty Capsules, 6 Controlled & Modified Release, 3 Solubilizers, 3 Emulsifying Agents, 2 API Stability Enhancers, 2 Coloring Agents, 2 Topical, 2 Rheology Modifiers, 1 Soft Gelatin

47 Fillers, Diluents & Binders
19 Disintegrants & Superdisintegrants
18 Direct Compression
16 Thickeners and Stabilizers
16 Lubricants & Glidants
15 Taste Masking
14 Chewable & Orodispersible Aids
12 Parenteral
12 Co-Processed Excipients
11 Coating Systems & Additives
11 Film Formers & Plasticizers
10 Granulation
8 Empty Capsules
6 Controlled & Modified Release
3 Solubilizers
3 Emulsifying Agents
2 API Stability Enhancers
2 Coloring Agents
2 Topical
2 Rheology Modifiers
1 Soft Gelatin

DIGITAL CONTENT

62 News #PharmaBuzz

62 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 18 Regulatory FDF Prices, 10 Annual Reports

1 US Medicaid Prescriptions
18 Regulatory FDF Prices
10 Annual Reports

MARKET PLACE

8 APIs, 6 FDF Dossiers

8 APIs
6 FDF Dossiers

PATENTS & EXCLUSIVITIES

36 US Patents, 3 Health Canada Patents

36 US Patents
3 Health Canada Patents

REF. STANDARDS & IMPURITIES

7 USP, 7 Others

7 USP
7 Others

$ API Ref.Price (USD/KG) : 680,068 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

36 All

01 36HELSINN HLTHCARE

filter Patent Number Reset all filters

36 All

01 28426450

02 18623826

03 28895586

04 18951969

05 39186357

06 19271975

07 29403772

08 29908907

09 19943515

10 19951016

11 210208073

12 110233154

13 210624911

14 110676440

15 210717721

16 310828297

17 110961195

18 211312698

19 211529362

20 111559523

21 112042494

22 212208109

filter API Patent Reset all filters

36 All

01 14Y

02 22Blank

filter FDF Patent Reset all filters

36 All

01 18Y

02 18Blank

filter Expiration Date Reset all filters

36 All

01 82030-11-18

02 32030-12-17

03 12031-09-09

04 142032-05-23

05 42035-09-25

06 62037-06-02

Product Main Page

01

HELSINN HLTHCARE

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

BePharma

Not Confirmed

HELSINN HLTHCARE

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-05-23

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

US Patent Number : 10208073

Drug Substance Claim :

Drug Product Claim :

Application Number : 210493

Patent Use Code : U-2301

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-05-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

HELSINN HLTHCARE

NETUPITANT; PALONOSETRON HYDROCHLORIDE

BePharma

Not Confirmed

HELSINN HLTHCARE

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-11-18

NETUPITANT; PALONOSETRON HYDROCHLORIDE

US Patent Number : 9943515

Drug Substance Claim :

Drug Product Claim :

Application Number : 205718

Patent Use Code : U-2293

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-11-18

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

HELSINN HLTHCARE

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

BePharma

Not Confirmed

HELSINN HLTHCARE

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-05-23

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

US Patent Number : 8895586

Drug Substance Claim :

Drug Product Claim :

Application Number : 210493

Patent Use Code : U-2301

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-05-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

HELSINN HLTHCARE

NETUPITANT; PALONOSETRON HYDROCHLORIDE

BePharma

Not Confirmed

HELSINN HLTHCARE

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-11-18

NETUPITANT; PALONOSETRON HYDROCHLORIDE

US Patent Number : 8623826

Drug Substance Claim :

Drug Product Claim :

Application Number : 205718

Patent Use Code : U-2293

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-11-18

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

HELSINN HLTHCARE

NETUPITANT; PALONOSETRON HYDROCHLORIDE

BePharma

Not Confirmed

HELSINN HLTHCARE

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-09-09

NETUPITANT; PALONOSETRON HYDROCHLORIDE

US Patent Number : 9271975

Drug Substance Claim :

Drug Product Claim :

Application Number : 205718

Patent Use Code : U-2293

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-09-09

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

HELSINN HLTHCARE

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

BePharma

Not Confirmed

HELSINN HLTHCARE

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-05-23

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

US Patent Number : 9403772

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 210493

Patent Use Code : U-2301

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-05-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

HELSINN HLTHCARE

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

BePharma

Not Confirmed

HELSINN HLTHCARE

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-11-18

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

US Patent Number : 9186357

Drug Substance Claim :

Drug Product Claim :

Application Number : 210493

Patent Use Code : U-2301

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-11-18

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

HELSINN HLTHCARE

NETUPITANT; PALONOSETRON HYDROCHLORIDE

BePharma

Not Confirmed

HELSINN HLTHCARE

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-11-18

NETUPITANT; PALONOSETRON HYDROCHLORIDE

US Patent Number : 9186357

Drug Substance Claim :

Drug Product Claim :

Application Number : 205718

Patent Use Code : U-2293

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-11-18

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

HELSINN HLTHCARE

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

BePharma

Not Confirmed

HELSINN HLTHCARE

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-05-23

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

US Patent Number : 8895586

Drug Substance Claim :

Drug Product Claim :

Application Number : 210493

Patent Use Code : U-2301

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-05-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

HELSINN HLTHCARE

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

BePharma

Not Confirmed

HELSINN HLTHCARE

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-05-23

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

US Patent Number : 9403772

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 210493

Patent Use Code : U-2301

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-05-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2
3
Last

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!